Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Fig. 2

YM101 synergized with MSA-2 in one-way MLR assay. a FACS for PD-L1 expression. Immature BMDCs were cultured with MSA-2 for one day and collected for flow cytometry. b One-way mixed lymphocyte reaction (MLR). Stimulating cells were BMDCs derived from BALB/c mice, while responding cells were spleen cells from C57BL/6 in the MLR assays. The mixed cells with YM101 or controls were cultured for four days. On day 5, cells were collected for CFSE dilution assay. c–g The synergistic effect between MSA-2 and YM101 in the MLR system with exogenous TGF-β1. The mixed cells with TGF-β1 and antibodies for four days. On day 5, the levels of cytokines in the supernatant were detected. The heatmap shows the scaled level of cytokines, and the dot plots present the quantitative values. *p < 0.05 means the significant difference compared to the vehicle (for a and b) or MSA-2 combined with YM101 (for d–g)

Back to article page